查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1830989

胃癌市场

Stomach Cancer Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

预计胃癌市场规模将从 2024 年的 51.5 亿美元扩大到 2031 年的 119.8 亿美元，2025 年至 2031 年的复合年增长率预计为 14.8%。

市场洞察与分析师观点：胃癌（或称胃癌）源自于胃内恶性细胞的异常与不受控制的增生。导致胃癌风险的因素包括年龄和饮食习惯。症状可能包括消化不良、胃痛、食慾不振、胃灼热和体重减轻。胃癌的治疗方案包括化疗、放射疗法和免疫疗法。胃癌市场的成长得益于该疾病发病率的上升、化疗、手术和标靶疗法等治疗方式的进步，以及旨在改善患者预后的持续研发。随着对早期诊断和个人化治疗策略的日益关注，预计胃癌治疗市场将在未来几年继续保持成长势头。

成长催化剂：医疗保健公司正在进行各种研发项目，以开发针对胃癌的创新疗法。此外，这些疗法正在临床试验中进行评估，新的治疗方法也不断发展和探索。一些值得关注的研发产品包括：

2022年12月，浙江多尔生物製品有限公司与默克公司达成临床试验合作，旨在评估多尔生物的抗Claudin18.2抗体DR30303与默克的抗PD-1疗法KEYTRUDA（帕博利珠单抗）联合治疗胃癌或胃食道结合部癌患者的疗效。协议规定，多尔生物将根据双方商定的方案进行一项实验研究，以评估DR30303合併KEYTRUDA在Claudin18.2阳性、局部晚期、不可切除或转移性胃癌或胃食道结合部癌患者中的安全性和有效性。 2022年11月，Triumvira Immunologics发表了其在研TAC-T细胞疗法CLDN18.2-TAC T和GUCY2C-TAC T的临床前研究结果，以及HER2特异性TAC-T产品的资料。该公司公布了其针对Claudin 18.2的新型T细胞抗原偶联剂(TAC)-T细胞候选药物用于治疗胃癌的最新资料。 2022年9月，Nuvectis Pharma, Inc.报告了NXP800在ARID1a突变胃癌临床前异种移植模型的阳性结果。在接受赋形剂或NXP800治疗后28天内评估了肿瘤体积，结果显示与对照组相比，肿瘤消退且生长显着受到抑制。因此，临床试验数量的增加提高了全球胃癌治疗的可近性，并对胃癌市场的成长产生了积极影响。

策略洞察报告细分和范围：胃癌市场按类型、治疗、给药途径、配销通路和地理细分。依类型，包括腺癌、胃肠道间质瘤、神经内分泌肿瘤、淋巴瘤等。在治疗方面，市场分为标靶和免疫治疗药物、化疗和合併药物等。市场依给药途径细分为口服、肠外及其他。分销管道包括医院药房、零售药房和网路药房。从地理上讲，市场分为北美（美国、加拿大和墨西哥）、欧洲（法国、德国、英国、西班牙、义大利和欧洲其他地区）、亚太地区（中国、印度、日本、澳洲、韩国和亚太其他地区）、中东和非洲（沙乌地阿拉伯、阿联酋、南非和中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷和南美洲和其他中美洲地区）。

細項分析：胃癌市场依类型分为腺癌、胃肠道间质瘤、神经内分泌肿瘤、淋巴瘤等。腺癌细分市场在2022年占据了相当大的市场份额，预计在2022-2030年期间将呈现最高的复合年增长率。

依治疗类型划分，市场分为标靶治疗药物和免疫治疗药物、化疗和合併用药以及其他药物。 2022年，化疗和联合用药领域占据了相当大的市场份额，而标靶治疗药物和免疫治疗药物领域预计将在2022年至2030年期间实现最高的复合年增长率。

根据给药途径，市场细分为口服、肠外给药和其他给药方式。口服给药在2022年占据了相当大的市场份额，预计在2022-2030年期间将以最快的复合年增长率增长。

就配销通路而言，市场分为医院药房、零售药房和线上药房。医院药房在2022年占据了相当大的市场份额，预计在2022-2030年期间将实现最高的复合年增长率。

区域分析：胃癌市场主要分为北美、欧洲、亚太地区、南美洲和中美以及中东和非洲。 2022 年，北美占据了相当大的市场份额，其中美国在该地区占有最大份额。北美市场的成长归因于胃癌发病率的上升、标靶癌症疗法的采用率的提高以及癌症研究和治疗设施中先进技术的可用性。美国癌症协会预测，2023 年将诊断出约 26,500 例新胃癌病例（男性 15,930 例，女性 10,570 例），预计约有 11,130 人（男性 6,690 例，女性 4,440 例）死于胃癌。北美拥有先进的癌症治疗方案，各公司正努力与该地区的老牌企业竞争。

此外，旨在开发针对胃癌患者的有效药物的临床试验数量不断增加，以及产品上市和获批数量的增加，预计将推动该地区市场的成长。 2021年4月，美国食品药物管理局 (FDA) 批准了百时美施贵宝的 Opdivo 合併氟嘧啶和铂类化疗，用于治疗晚期或转移性胃癌和食道腺癌患者。这些进展预计将在预测期内支持该地区的市场成长。

胃癌市场报告范围产业发展与未来机会：全球胃癌市场主要参与者的几项措施重点介绍如下：

2021年1月，阿斯特捷利康和第一三共株式会社获得美国食品药物管理局（FDA）批准Enhertu用于治疗晚期或转移性HER2阳性胃腺癌成年患者。竞争格局与主要公司：胃癌市场的知名企业包括百时美施贵宝公司、诺华公司、默克公司、礼来公司、Biocon公司、梯瓦製药工业有限公司、Celltrion Healthcare有限公司、三星Bioepis公司、辉瑞公司和益普生製药公司。这些公司专注于推出新的高科技产品、增强现有产品线并拓展地理范围以满足日益增长的全球需求。

目录

第一章：简介

第 2 章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：胃癌市场概况

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：胃癌市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：胃癌市场－全球市场分析

  • 胃癌 - 全球市场概览
  • 胃癌－全球市场及2030年预测

第七章：胃癌​​市场-收入分析-按类型，2020-2030

  • 概述
  • 腺癌
  • 胃肠道间质瘤
  • 神经内分泌肿瘤
  • 淋巴瘤
  • 其他的

第 8 章：胃癌市场 - 收入分析 - 依治疗方法，2020-2030 年

  • 概述
  • 标靶和免疫治疗药物
  • 化疗和合併用药
  • 其他的

第九章：胃癌市场-收入分析-依给药途径，2020-2030

  • 概述
  • 口服
  • 肠外
  • 其他的

第 10 章：胃癌市场 - 收入分析 - 按配销通路，2020-2030 年

  • 概述
  • 医院药房
  • 零售药局
  • 网路药局

第 11 章：胃癌市场 - 收入分析，2020-2030 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 12 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 13 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 14 章：胃癌市场 - 关键公司简介

  • Bristol Myers Squibb Company
  • Novartis AG
  • Merck and Co., Inc.
  • Eli Lilly and Company
  • Biocon
  • Teva Pharmaceutical Industries Ltd.
  • Celltrion Healthcare Co., Ltd.
  • Samsung Bioepis
  • Pfizer Inc.
  • Ipsen pharma

第 15 章：附录

简介目录
Product Code: TIPRE00004053

The stomach cancer market is anticipated to expand from US$ 5.15 billion in 2024 to US$ 11.98 billion by 2031, with a projected CAGR of 14.8% from 2025 to 2031.

Market Insights and Analyst Perspective:Stomach cancer, or gastric cancer, arises from the abnormal and uncontrolled proliferation of malignant cells in the stomach. Factors contributing to the risk of stomach cancer include age and dietary habits. Symptoms may include indigestion, stomach pain, loss of appetite, heartburn, and weight loss. Treatment options for stomach cancer include chemotherapy, radiation therapy, and immunotherapy. The growth of the stomach cancer market is driven by the rising incidence of the disease, advancements in treatment modalities such as chemotherapy, surgery, and targeted therapies, as well as ongoing research and development aimed at enhancing patient outcomes. With a growing focus on early diagnosis and personalized treatment strategies, the stomach cancer treatment market is expected to continue its growth trajectory in the coming years.

Growth Catalysts:Healthcare companies are engaging in various research and development initiatives to create innovative treatments for gastric cancer. Furthermore, these treatments are undergoing evaluation in clinical trials, with new methodologies being continuously developed and explored. Some notable products in the pipeline include:

In December 2022, Zhejiang Doer Biologics Co., Ltd entered into a clinical trial collaboration with Merck & Co., Inc. to assess Doer Bio's anti-Claudin18.2 antibody DR30303 in conjunction with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for patients with gastric or gastroesophageal junction cancer. The agreement stipulated that Doer Bio would conduct an experimental study based on a mutually agreed protocol to evaluate the safety and efficacy of DR30303 combined with KEYTRUDA in Claudin18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer patients.In November 2022, Triumvira Immunologics announced preclinical findings for its investigational TAC-T cell therapies CLDN18.2-TAC T and GUCY2C-TAC T, along with data on HER2-specific TAC-T products. The company presented updated data on its novel T cell antigen coupler (TAC)-T cell candidate targeting Claudin 18.2 for gastric cancer treatment.In September 2022, Nuvectis Pharma, Inc. reported positive results for NXP800 in a preclinical xenograft model of ARID1a-mutated gastric carcinoma. Tumor volumes were assessed over 28 days after treatment with either a vehicle or NXP800, showing tumor regression and significant growth inhibition compared to the control.Thus, the increasing number of clinical trials enhances the availability of gastric cancer treatments globally, positively influencing the growth of the stomach cancer market.

Strategic Insights Report Segmentation and Scope:The stomach cancer market is segmented by type, treatment, route of administration, distribution channel, and geography. By type, it includes adenocarcinomas, gastrointestinal stromal tumors, neuroendocrine tumors, lymphoma, and others. In terms of treatment, the market is classified into targeted and immunotherapy drugs, chemotherapy and combination drugs, and others. The market is segmented by route of administration into oral, parenteral, and others. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Geographically, the market is divided into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:The stomach cancer market is categorized by type into adenocarcinomas, gastrointestinal stromal tumors, neuroendocrine tumors, lymphoma, and others. The adenocarcinomas segment held a substantial market share in 2022 and is projected to exhibit the highest CAGR during 2022-2030.

By treatment, the market is divided into targeted and immunotherapy drugs, chemotherapy and combination drugs, and others. In 2022, the chemotherapy and combination drugs segment accounted for a significant market share, while the targeted and immunotherapy drugs segment is expected to show the highest CAGR from 2022 to 2030.

Regarding the route of administration, the market is segmented into oral, parenteral, and others. The oral segment held a notable market share in 2022 and is anticipated to grow at the fastest CAGR during 2022-2030.

In terms of distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held a significant market share in 2022 and is expected to register the highest CAGR during 2022-2030.

Regional Analysis:The stomach cancer market is primarily segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America captured a significant market share, with the US holding the largest share in the region. The growth of the market in North America is attributed to the rising prevalence of gastric cancer, increased adoption of targeted cancer therapies, and the availability of advanced technologies in cancer research and treatment facilities. The American Cancer Society projected approximately 26,500 new cases of gastric cancer (15,930 in males and 10,570 in females) to be diagnosed in 2023, with around 11,130 deaths (6,690 males and 4,440 females) expected due to gastric cancer. North America is well-equipped with advanced treatment options for cancer, and companies are striving to compete with established players in the region.

Additionally, the growing number of clinical trials aimed at developing effective drugs for gastric cancer patients, along with an increase in product launches and approvals, is expected to drive market growth in the region. In April 2021, the Food and Drug Administration (FDA) approved Bristol Myers Squibb's Opdivo, in combination with fluoropyrimidine and platinum-based chemotherapy, for treating patients with advanced or metastatic gastric cancer and esophageal adenocarcinoma. Such developments are likely to support market growth in the region during the forecast period.

Stomach Cancer Market Report Scope Industry Developments and Future Opportunities:Several initiatives by key players in the global stomach cancer market are highlighted below:

In January 2021, AstraZeneca and Daiichi Sankyo Company received FDA approval for Enhertu to treat adult patients with advanced or metastatic HER2-positive gastric adenocarcinoma.

Competitive Landscape and Key Companies:Prominent players in the stomach cancer market include Bristol Myers Squibb Company, Novartis AG, Merck & Co., Inc., Eli Lilly and Company, Biocon, Teva Pharmaceutical Industries Ltd, Celltrion Healthcare Co., Ltd, Samsung Bioepis, Pfizer Inc., and Ipsen Pharma. These companies are focused on launching new high-tech products, enhancing existing offerings, and expanding geographically to meet the increasing global demand.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Stomach Cancer Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Stomach Cancer Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Stomach Cancer Market - Global Market Analysis

  • 6.1 Stomach Cancer - Global Market Overview
  • 6.2 Stomach Cancer - Global Market and Forecast to 2030

7. Stomach Cancer Market - Revenue Analysis (USD Million) - By Type, 2020-2030

  • 7.1 Overview
  • 7.2 Adenocarcinomas
  • 7.3 Gastrointestinal Stromal Tumors
  • 7.4 Neuroendocrine Tumors
  • 7.5 Lymphoma
  • 7.6 Others

8. Stomach Cancer Market - Revenue Analysis (USD Million) - By Treatment, 2020-2030

  • 8.1 Overview
  • 8.2 Targeted and Immunotherapy Drugs
    • 8.2.1 Monoclonal Antibody
    • 8.2.2 Human Epidermal Growth Factor Receptor 2 (HER2)
    • 8.2.3 Checkpoint Inhibitors
  • 8.3 Chemotherapy and Combination Drugs
  • 8.4 Others

9. Stomach Cancer Market - Revenue Analysis (USD Million) - By Route of Administration, 2020-2030

  • 9.1 Overview
  • 9.2 Oral
  • 9.3 Parenteral
  • 9.4 Others

10. Stomach Cancer Market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030

  • 10.1 Overview
  • 10.2 Hospital Pharmacies
  • 10.3 Retail Pharmacies
  • 10.4 Online Pharmacies

11. Stomach Cancer Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 11.1 North America
    • 11.1.1 North America Stomach Cancer Market Overview
    • 11.1.2 North America Stomach Cancer Market Revenue and Forecasts to 2030
    • 11.1.3 North America Stomach Cancer Market Revenue and Forecasts and Analysis - By Type
    • 11.1.4 North America Stomach Cancer Market Revenue and Forecasts and Analysis - By Treatment
    • 11.1.5 North America Stomach Cancer Market Revenue and Forecasts and Analysis - By Route of Administration
    • 11.1.6 North America Stomach Cancer Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 11.1.7 North America Stomach Cancer Market Revenue and Forecasts and Analysis - By Countries
      • 11.1.7.1 United States Stomach Cancer Market
        • 11.1.7.1.1 United States Stomach Cancer Market, by Type
        • 11.1.7.1.2 United States Stomach Cancer Market, by Treatment
        • 11.1.7.1.3 United States Stomach Cancer Market, by Route of Administration
        • 11.1.7.1.4 United States Stomach Cancer Market, by Distribution Channel
      • 11.1.7.2 Canada Stomach Cancer Market
        • 11.1.7.2.1 Canada Stomach Cancer Market, by Type
        • 11.1.7.2.2 Canada Stomach Cancer Market, by Treatment
        • 11.1.7.2.3 Canada Stomach Cancer Market, by Route of Administration
        • 11.1.7.2.4 Canada Stomach Cancer Market, by Distribution Channel
      • 11.1.7.3 Mexico Stomach Cancer Market
        • 11.1.7.3.1 Mexico Stomach Cancer Market, by Type
        • 11.1.7.3.2 Mexico Stomach Cancer Market, by Treatment
        • 11.1.7.3.3 Mexico Stomach Cancer Market, by Route of Administration
        • 11.1.7.3.4 Mexico Stomach Cancer Market, by Distribution Channel
  • 11.2 Europe
    • 11.2.1 Germany
    • 11.2.2 France
    • 11.2.3 Italy
    • 11.2.4 Spain
    • 11.2.5 United Kingdom
    • 11.2.6 Rest of Europe
  • 11.3 Asia-Pacific
    • 11.3.1 Australia
    • 11.3.2 China
    • 11.3.3 India
    • 11.3.4 Japan
    • 11.3.5 South Korea
    • 11.3.6 Rest of Asia-Pacific
  • 11.4 Middle East and Africa
    • 11.4.1 South Africa
    • 11.4.2 Saudi Arabia
    • 11.4.3 U.A.E
    • 11.4.4 Rest of Middle East and Africa
  • 11.5 South and Central America
    • 11.5.1 Brazil
    • 11.5.2 Argentina
    • 11.5.3 Rest of South and Central America

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Stomach Cancer Market - Key Company Profiles

  • 14.1 Bristol Myers Squibb Company
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Novartis AG
  • 14.3 Merck and Co., Inc.
  • 14.4 Eli Lilly and Company
  • 14.5 Biocon
  • 14.6 Teva Pharmaceutical Industries Ltd.
  • 14.7 Celltrion Healthcare Co., Ltd.
  • 14.8 Samsung Bioepis
  • 14.9 Pfizer Inc.
  • 14.10 Ipsen pharma

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud